0.69
-0.4977(-41.82%)
Currency In USD
| Previous Close | 1.19 |
| Open | 1.07 |
| Day High | 1.08 |
| Day Low | 0.67 |
| 52-Week High | 4.02 |
| 52-Week Low | 0.67 |
| Volume | 6.19M |
| Average Volume | 1.22M |
| Market Cap | 33.47M |
| PE | -0.41 |
| EPS | -1.7 |
| Moving Average 50 Days | 1.77 |
| Moving Average 200 Days | 2.01 |
| Change | -0.5 |
If you invested $1000 in BioAtla, Inc. (BCAB) since IPO date, it would be worth $22.32 as of December 21, 2024 at a share price of $0.692. Whereas If you bought $1000 worth of BioAtla, Inc. (BCAB) shares 3 years ago, it would be worth $34.67 as of December 21, 2024 at a share price of $0.692.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
GlobeNewswire Inc.
Yesterday at 2:00 PM GMT
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the tr
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
GlobeNewswire Inc.
Dec 16, 2024 1:00 PM GMT
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KR
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
GlobeNewswire Inc.
Dec 10, 2024 1:00 PM GMT
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, toda